Menogaril: a new anthracycline agent entering clinical trials

Abstract

Menogaril [menogarol, 7(R)-O-methymogarol, 7-OMEN] is a new anthracycline agent which was chosen for clinical trials based on: a) broad spectrum activity against a panel of murine tumors b) lower cardiotoxicity than doxorubicin in the chronic rabbit model c) differences in biochemical effects from other anthracyclines suggesting a possible difference in mechanism of action d) murine antitumor activity by oral as well as parenteral routes. broad spectrum activity against a panel of murine tumors lower cardiotoxicity than doxorubicin in the chronic rabbit model differences in biochemical effects from other anthracyclines suggesting a possible difference in mechanism of action murine antitumor activity by oral as well as parenteral routes. Biochemical studies indicated that, in comparison to doxorubicin, menogaril is bound weakly to DNA, inhibits RNA synthesis less, and has different cell cycle phase-specific cytotoxicity. Pharmacology studies in the mouse and dog using HPLC analytical methodology have shown multiexponential clearance from plasma and metabolism of menogaril to a material which co-chromatographs with N-demethylmenogaril in addition to at least two other metabolites of unknown structure. Oral bioavailability studies in the mouse showed significant absorption of menogaril from the gastrointestinal tract followed by first-pass metabolism. In acute toxicity studies in the rat, the dog, and the monkey, dose-related myelosuppression and gastrointestinal toxicity predominated. Phase I clinical trails on menogaril are currently in progress on a variety of schedules.

Topics

4 Figures and Tables

Download Full PDF Version (Non-Commercial Use)